Immitra Bio is developing an in vivo gene-editing platform that does not depend on the mutation, with a lead candidate against an inherited anaemia. It has raised CHF 2.4 million in pre-seed funding, including CHF 150,000 non-dilutive, led by Backbone Ventures and co-led by OCCIDENT, for preclinical studies.
- Announced on
- Round
- Pre-seed
- Amount
- CHF 2.4 M
- Location
- Geneva
- Sector
- Biotech & life sciences
Investors
- Backbone Ventures lead
- Occident Group lead
- Another VC
- Kickfund
- Venture Kick
- Zürcher Kantonalbank
- FONGIT
- ETH Foundation
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic